general overview of asco gi 2018 -...
TRANSCRIPT
General Overview of ASCO GI 2018
Alberto Zaniboni Oncologia Medica
Fondazione Poliambulanza - Brescia
Le mie disclosures
Research grants: Roche, Novartis, Pfizer, Astra Zeneca, Janssen, Boheringer
Advisory boards / Speaker Bureau: Amgen, Merk Serono, Bayer, Servier, BMS, Lilly, Sanofi
ASCO GI 2018
Esophageal and GEJ Adenocarcinoma: Current Outcomes + Future Directions
Presented By David Ilson at 2018 Gastrointestinal Cancers Symposium
Esophageal and GEJ Adenocarcinoma: Current Outcomes + Future Directions
Presented By David Ilson at 2018 Gastrointestinal Cancers Symposium
FLOT4 Study Design
Presented By Jaffer Ajani at 2018 Gastrointestinal Cancers Symposium
Since 2006: 5-Y OS nearly doubled compared with surgery alone
Presented By Salah-Eddin Al-Batran at 2018 Gastrointestinal Cancers Symposium
Slide 15
Presented By Salah-Eddin Al-Batran at 2018 Gastrointestinal Cancers Symposium
ECF or any of its modifications should be abandoned
Presented By Jaffer Ajani at 2018 Gastrointestinal Cancers Symposium
FLOT should be reserved for an occasional patient
Presented By Jaffer Ajani at 2018 Gastrointestinal Cancers Symposium
RAINFALL: A randomized, double-blind, placebo-controlled phase 3 study of cisplatin (Cis) plus capecitabine (Cape) or 5FU with or without ramucirumab (RAM) as first-line therapy in
patients with metastatic gastric or gastroesophageal junction (G-GEJ) adenocarcinoma.
Presented By Charles Fuchs at 2018 Gastrointestinal Cancers Symposium
RAINFALL Trial Design:
Presented By Charles Fuchs at 2018 Gastrointestinal Cancers Symposium
Intraperitoneal immunotherapy with the bispecific anti-EpCAM x anti-CD3 directed antibody catumaxomab for patients with peritoneal carcinomatosis from gastric cancer – final results
of a randomized phase II AIO trial
Presented By Florian Lordick at 2018 Gastrointestinal Cancers Symposium
Catumaxomab (CATU)
Presented By Florian Lordick at 2018 Gastrointestinal Cancers Symposium
ASCO GI 2018
Duration of Adjuvant Therapy for Colon Cancer: Is 3 Months Enough?<br />The U.S. Perspective
Presented By Jeffrey Meyerhardt at 2018 Gastrointestinal Cancers Symposium
Duration of Adjuvant Therapy for Colon Cancer – is 3 Months Enough?<br />The European Perspective
Presented By Timothy Iveson at 2018 Gastrointestinal Cancers Symposium
6 months after ASCO: How are IDEA Results Being Interpreted/Incorporated
Presented By Jeffrey Meyerhardt at 2018 Gastrointestinal Cancers Symposium
ARS 1: 34-year-old male with well differentiated, T3 colon cancer with 1 of 15 positive lymph nodes. What would you recommend for adjuvant therapy?
Presented By Jeffrey Meyerhardt at 2018 Gastrointestinal Cancers Symposium
Colorectal Cancer With Peritoneal Metastasis: A Regional Disease Requiring Regional Therapy<br />CON
Presented By Garrett Nash at 2018 Gastrointestinal Cancers Symposium
Role of (Neo) Adjuvant Chemotherapy for Rectal Cancer<br />The European approach
Presented By Cornelis Van De Velde at 2018 Gastrointestinal Cancers Symposium
Nivolumab in Patients With DNA Mismatch <br />Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer: Long-Term Survival According to Prior Line of Treatment
From <br />CheckMate-142
Presented By Michael Overman at 2018 Gastrointestinal Cancers Symposium
Nivolumab + Ipilimumab Combination in Patients <br />With DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer: <br />First Report of the Full
Cohort From CheckMate-142
Presented By Thierry Andre at 2018 Gastrointestinal Cancers Symposium
Slide 1
Presented By Johanna Bendell at 2018 Gastrointestinal Cancers Symposium
Slide 1
Presented By Kohei Shitara at 2018 Gastrointestinal Cancers Symposium
ASCO GI 2018
Slide 1
Presented By Juan Valle at 2018 Gastrointestinal Cancers Symposium
Stereotactic Body Radiotherapy (SBRT); What Role Does Focal Radiotherapy Play for Hepatocellular Carcinoma
Presented By Jinsil Seong at 2018 Gastrointestinal Cancers Symposium
Slide 1
Presented By Ann-Lii Cheng at 2018 Gastrointestinal Cancers Symposium
Conclusions<br />(2018 perspective of systemic tx for HCC)
Presented By Ann-Lii Cheng at 2018 Gastrointestinal Cancers Symposium
Slide 2
Presented By Jordi Bruix at 2018 Gastrointestinal Cancers Symposium
Slide 1
Presented By Masatoshi Kudo at 2018 Gastrointestinal Cancers Symposium
KEYNOTE-224: Pembrolizumab in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib
Presented By Andrew Zhu at 2018 Gastrointestinal Cancers Symposium
Cabozantinib versus placebo in patients with advanced hepatocellular carcinoma who have received prior sorafenib: results from the randomized phase 3 CELESTIAL trial
Presented By Ghassan Abou-Alfa at 2018 Gastrointestinal Cancers Symposium
Slide 1
Presented By Ramesh Ramanathan at 2018 Gastrointestinal Cancers Symposium
ABSTRACT 204
Presented By Pascal Hammel at 2018 Gastrointestinal Cancers Symposium